A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults

Trial Profile

A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Acumapimod (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms AETHER
  • Sponsors Mereo BioPharma
  • Most Recent Events

    • 20 Mar 2018 According to a Mereo BioPharma media release, positive data from the study will be presented at the American Thoracic Society (ATS) 2018 International Conference.
    • 12 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2017 Top-line results published in the Mereo BioPharma Group Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top